Matinas BioPharma Holdings, Inc. (MTNB)
NYSEAMERICAN: MTNB · Real-Time Price · USD
0.550
-0.030 (-5.14%)
At close: Mar 3, 2025, 4:00 PM
0.560
+0.010 (1.80%)
After-hours: Mar 3, 2025, 7:30 PM EST
MTNB Employees
Matinas BioPharma Holdings had 32 employees as of December 31, 2023. The number of employees decreased by 2 or -5.88% compared to the previous year.
Employees
32
Change (1Y)
-2
Growth (1Y)
-5.88%
Revenue / Employee
n/a
Profits / Employee
-$660,375
Market Cap
2.80M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
MTNB News
- 18 days ago - Matinas BioPharma Announces Agreement for the Acquisition of Preferred Stock and Appointment of Dr. Robin L. Smith to the Board of Directors - GlobeNewsWire
- 25 days ago - Matinas BioPharma Appoints Evelyn D'An to Board of Directors as Audit Committee Chair - GlobeNewsWire
- 7 weeks ago - Matinas BioPharma Receives NYSE Noncompliance Notice - GlobeNewsWire
- 4 months ago - Matinas BioPharma Announces the Termination of MAT2203 Partnership Negotiations and Implements Immediate Workforce Reduction - GlobeNewsWire
- 7 months ago - Matinas BioPharma Holdings, Inc. (MTNB) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 7 months ago - Matinas BioPharma Reports Second Quarter 2024 Financial Results and Provides a Business Update - GlobeNewsWire
- 7 months ago - Matinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2024 Financial Results and Provide a Business Update on August 14, 2024 - GlobeNewsWire
- 9 months ago - Matinas BioPharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in its Oral MAT2203 Compassionate/Expanded Use Access Program - GlobeNewsWire